Cellebrite DI Q2 2025 Earnings Call Transcript

Quartr
Provided by Quartr
August 14, 2025

Key Takeaways

  • Positive Sentiment: ARR grew 21% year-over-year to $419 million, with adjusted EBITDA up 29% and a free cash flow margin of 25.6%.
  • Positive Sentiment: Product momentum continues as 40% of customers have upgraded to Insights, 20% of ARR now from cloud/SaaS, and Guardian ARR rose over 100% year-over-year.
  • Positive Sentiment: The Keryllium acquisition expands Celebrite’s addressable market with ARM virtualization technology and has already secured a $500 K sale to a European intelligence agency.
  • Negative Sentiment: Celebrite lowered its 2025 ARR growth guidance by roughly four points to 16–20% and revenue guidance to 16–18% amid delayed US federal spending.
  • Neutral Sentiment: Tom Hogan was appointed permanent CEO after serving as interim, following his complete remission from stage four non-Hodgkin’s lymphoma.
AI Generated. May Contain Errors.
Earnings Conference Call
Cellebrite DI Q2 2025
00:00 / 00:00

Transcript Sections

Skip to Participants
Operator

to the Celebrite Second Quarter twenty twenty five Financial Results Conference Call. At this time, participants have been placed on a listen only mode, and the floor will be open for your questions following the presentation. Please press 1 on your telephone keypad. If at any point your question has been answered, you may remove yourself from the queue by pressing 2.

Operator

So others can hear your questions clearly, we ask that you pick up your handset for best sound quality. Lastly, if you should require operator assistance, please press 0. I would now like to turn the call over to your first speaker today, Mr. Andrew Kramer. Mr. Kramer, the floor is yours.

Andrew Kramer
Andrew Kramer
VP - IR at Cellebrite DI

Thank you very much, Angela. Good morning, everybody. Welcome to Celebrite's second quarter twenty twenty five financial results conference call. I'm joined here today at our U. S.

Andrew Kramer
Andrew Kramer
VP - IR at Cellebrite DI

Headquarters outside of Washington, D. C. Our primary speakers on the call will be Tom Hogan, Celebrite's CEO and David Barter, Celebrite's CFO. Also with us in the room are Dana Kerner, our former CFO and Marcus Jewell, our CRO. Joining us remotely will be Adam Klommer, Celebrite's Chairman of the Board, who will also have some remarks for today.

Andrew Kramer
Andrew Kramer
VP - IR at Cellebrite DI

This call is being recorded and a replay of the recording will be made available on our website shortly after the call and eventually we will post a copy of our prepared remarks. Please note that a copy of today's press release and financial statements, including GAAP to non GAAP reconciliations is available on the Investor Relations website at investors.celebrite.com. In addition to the press release, we've also posted an investor presentation that provides a detailed overview of our business and recent financial performance along with publishing the quarterly financial tables and supplemental historical financial information for each quarter for the past, three years, it's available on our Investor Relations website. Also, unless stated otherwise, our discussion of our second quarter twenty twenty five financial metrics as well as the financial metrics provided in our outlook will be done on a non GAAP basis only, and all historical comparisons are with the 2024. In addition, please note that statements made on this call that are not statements of historical facts constitute forward looking statements.

Andrew Kramer
Andrew Kramer
VP - IR at Cellebrite DI

All forward looking statements are subject to risks and uncertainties and other factors that could cause matters expressed or implied by those forward looking statements not to occur. They could also cause actual results to differ materially from historical results and or from forecasts. Some of these forward looking statements are discussed, under the heading Risk Factors and elsewhere in the company's annual report on Form 20 F filed with the SEC on 03/18/2025. The company does not undertake to update any forward looking statements to reflect future events or circumstances. In terms of today's agenda, Adam Klammer will share his thoughts on our CEO announcement.

Andrew Kramer
Andrew Kramer
VP - IR at Cellebrite DI

Tom will then provide a brief review of our quarterly performance, discuss key strategic achievements and milestones and offer his perspective on market conditions and the outlook for 2025. Donna Gerner will offer some brief, parting thoughts before, she retires, and Dave Barter will review the quarterly results and cover our outlook in more detail. And with that said, I'll now turn the call over to Adam Klammer. Adam, to you.

Adam Clammer
Adam Clammer
Chairman at Cellebrite DI

Thank you, Andy. It's a pleasure to be on today's call to briefly share the board's perspective on the appointment of Tom Hogan as Celebrite's CEO. Tom has long been the preferred choice of our board to serve as CEO, given his vast technology experience, his intense focus on strategy and intimacy with Celebrite's executive team, workforce, and customers gained over the last two years. Since joining Celebrite as Executive Chairman in August 2023 and continuing through his service as Interim CEO over the past eight months, Tom has played an important active role in every major initiative that has helped drive substantial value creation. His passion for Celebrite is tangible and infectious.

Adam Clammer
Adam Clammer
Chairman at Cellebrite DI

As Celebrite's chair and the managing partner of one of the company's largest shareholders, I could not be happier. Given that backdrop, you're likely wondering why it took so long for this appointment to occur. In the 2024, Tom was diagnosed with stage four non Hodgkin's lymphoma that precluded his ability to commit to serving as Celebrite CEO when the company announced its succession plans in 2024. At the time of Yossi's departure, Tom was on the back end of six months of chemotherapy at MD Anderson. He finished up his final treatments in December with his cancer fortunately in complete remission.

Adam Clammer
Adam Clammer
Chairman at Cellebrite DI

It was the board's strong desire and preference to retain Tom as the full time CEO, given the performance of the company since his arrival. I would remind the shareholders that despite the pullback in the stock price this year, Celebrite's value has more than doubled since Tom joined as Executive Chairman, mentoring Yossi and working closely with the team. Tom was willing and able to step in as interim CEO on January 1, But given the rigorous demands of a global CEO role, he wanted time to fully recover and confirm his ability to run at 120% and provide the leadership this company deserves. Given that backdrop, our board executed a thorough external search that yielded a number of very qualified candidates. This is a fabulous company, and the position attracted substantial interest.

Adam Clammer
Adam Clammer
Chairman at Cellebrite DI

We had multiple highly qualified prior public CEO experienced candidates that wanted this position, and we were prepared to go down that path if necessary. Fortunately, Tom's cancer has remained in full remission. As he has steadily regained his energy and stamina, we were thrilled when Tom raised his hand to remove the interim designation, which made our choice very easy. The board is unanimous in its conviction that Tom is the right individual to lead Celebrite, providing valuable continuity for the company, its people, shareholders and customers. Celebrite's future is incredibly bright.

Adam Clammer
Adam Clammer
Chairman at Cellebrite DI

Despite the near term uncertainty with U. S. Federal spending, this company is making an impact with customers while delivering durable, profitable growth and outstanding free cash flow. Myself and the board have confidence in the strategic initiatives already underway, some of which Tom and Dave will discuss today and those that will be further developed and executed on over the coming quarters. It will elevate the company's value with customers and lead to a stronger Celebrite.

Adam Clammer
Adam Clammer
Chairman at Cellebrite DI

Tom's appointment as CEO is a great outcome for Celebrite, the shareholders, its people and its customers. That concludes my comments and I will now hand the call over to Tom.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

Adam, thanks for the kind words. And as you know, I look forward to the next chapter together and completely share your optimism for the future of this company. So let me jump in. First, we see 2025, playing out largely as originally planned in the majority of our businesses with The U. S.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

State And Local Government and Latin America positioned actually to deliver exceptional full year results. As we shared in our last call, a variety of changes within the U. S. Fed sector has resulted in atypical spending activity and constrained visibility into the timing of new orders. These dynamics, along with our ongoing focus on the responsible management of our cost structure, have informed our revised 2025 financial targets, some up and some down.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

I'll discuss current market conditions and our full year 2025 outlook in more detail shortly, but first I'd like to address several important developments and achievements that are enhancing Celebrite's clarity and our confidence around our strategic direction, leadership and new vectors of growth. Let's begin with Celebrite's strategic direction. Despite current spending challenges, several important KPIs illustrate that our value proposition continues to resonate in the market and that we're making important progress against many of our top 2025 priorities. First, in terms of Insights, our flagship digital forensic software, we continue to see customers upgrade from our legacy offerings to our digital investigation platform. At the end of the second quarter, Insight's been deployed by over 40% of our license base and is tracking comfortably ahead of our full year objective for conversions.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

Perhaps more importantly, our NPS scores on Insight's technical capabilities, including usability and workflows, device support and decoding have continued to trend favorably. Second, we continue to see strong adoption of our cloud and SaaS based solutions, which are now 20% of total ARR. More specifically, Guardian continues to gain traction with customers. This product has outstanding market fit, enabling more efficient management of the examination process, greater collaboration and strong chain of custody. ARR for Guardian grew by more than 100% year on year now for the fourth consecutive quarter.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

Much of Guardian's growth to date is from U. S. SLG customers, but it's been further bolstered by inroads this quarter in Latin America and The UK, while also closing the first Guardian deal, in Australia. Our pipeline for Guardian also remains strong and is accelerating as we position the strategic offering for other European markets over the coming quarters. Third, we're gaining important momentum in the global defense and intelligence sector, which was approximately 25% of our international ARR last year.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

We believe shifting budgetary priorities will fuel an acceleration of spending in this segment, which we are already starting to capture in our European region. Finally, in addition to continued growth with Insights and Guardian, our contributions from Pathfinder also improved and accelerated due to strength in new bookings combined with improvements in customer retention. In addition to this progress, we took an important strategic step forward in June when we announced our agreement to acquire Keryllium. We believe this is an important transaction that will accelerate innovation, expand our addressable market and help fuel long term growth across both our private and public sector businesses. Keryllium's ARM virtualization technology brings vulnerability and penetration testing to the wide range of ARM based endpoints, including smartphones, tablets, laptops, drones and IoT devices.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

We know firsthand just how powerful Keryllium's technology is. For the past five years, our internal mobile research teams have been using Keryllium's mobile vulnerability solution to efficiently evolve and advance our lawful access capabilities. Keryllium's mobile vulnerability research solution clearly expands our addressable market and specifically in the defense and intelligence sector. Based on the nearly immediate post announcement interest in the Keryllium solutions, we quickly executed a reseller agreement, which we closed roughly three weeks ago. And within two weeks of closing that reseller agreement, closed our first sale with a European intelligence agency for nearly $500,000 And we think this use case has broad applicability across the global intelligence community and gives you some insight, to our enthusiasm around the opportunity for significant growth post close.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

To that point, we clearly expect that Keryllium will be an accelerant to Celebrite's overall growth. And Dave will share some details on the transaction in just a few minutes. Let me turn to innovation and I want to highlight three areas. First, late last month, we announced that the Department of Justice will serve as the official sponsoring agency for Celebrite's FedRAMP High Authorization to Operate or the acronym ATO that you'll hear quite frequently. This ATO designation will cover our solutions delivered on the Celebrite Government Cloud, namely Insights and Guardian.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

The sponsorship is the critical next step required for the Celebrite Government Cloud to advance from its current FedRAMP Ready designation to in process. It marks a major milestone that significantly accelerates Celebrite's journey toward a full ATO, which will enable us to sell the breadth of our cloud assets to our installed base of U. S. Federal agency customers. We look forward to working with the DOJ to elevate their productivity, efficiency and efficacy with Guardian and the breadth of our cloud based product line.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

The second area is mobile research. We continue to invest significant resources, both people and dollars to keep pace with the mobile phone OEMs. Last month, we released a powerful new update to our Unlock software that covers more than 100 Android OEMs and thousands of models. This milestone underscores our long standing technological leadership for Android smartphones, which have more than 70% of global market share. This progress complements our ongoing focus and capabilities on the iOS ecosystem.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

We remain committed to extending our leadership position in providing lawful mobile access to law enforcement, defense and intelligence agencies across the world's democratized nations. Finally, AI continues to be a critical enabling technology that is powering our entire platform. Our commitment to innovation in this area remains the highest priority as we envision radically improved systems and solutions powered by GenAI. The good news is much of this innovation is already being delivered real time in our newest releases of Guardian with more to come over the coming months. With respect to leadership, since I joined Celebrite two years ago, we've worked diligently to strengthen our management team by recruiting executives with proven experience and relevant domain expertise at leading technology companies with global scale and impact.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

We applied that same philosophy to the appointment of Dave Barter as our new CFO. Dave brings proven credentials as a public company CFO at top software and SaaS businesses. While we're thrilled to have Dave on board, it also means saying goodbye to Donna Gerner, who will be retiring from Celebrite effectively after today's call. Donna's financial and accounting acumen, her intimate knowledge of our business, her work ethic and her passion enabled her to play a major role in Celebrite's success over the past eleven years. Donna, on behalf of everybody affiliated with Celebrite, I want to thank you for everything you've done for us and wish you all of the health and happiness you rightfully earned and deserve.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

And let me invite you to just say a few words to the folks on the line.

Dana Gerner
Dana Gerner
Advisor, CFO at Cellebrite DI

Well, thank you very much, Tom, for your kind words and for the partnership and the trust that you gave me over the past two years. It was remarkable. And I will keep my comments brief and directly from my heart. I spent the last eleven years journey in Cerebright and it was exciting, challenging, rewarding. I've been able to work with amazing people and teams, including many of you in the investment community.

Dana Gerner
Dana Gerner
Advisor, CFO at Cellebrite DI

I want to grant special thanks to my finance and ops teams and leaders who met with a can do attitude any challenge they've asked for us. I am very proud of you. And Dave, we spent the last weeks working together. No doubt Tom and the board has selected a great successor to the CFO role. Though it is still surreal that I say goodbye today, it is now the time for me to harness my experience, knowledge, and skills I gained in more than thirty five years as CFO in business, and put it to good use, giving back to my community.

Dana Gerner
Dana Gerner
Advisor, CFO at Cellebrite DI

And of course, I look forward to watching Cerberus try from the sidelines. And I'm sorry that I'm a little bit, excited, but I will now turn the call back to you, Tom.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

Donna, thank you, and thank you again. And we wish you all the best and we I think I can probably speak for all of us here and on the phone, we look forward to monitoring the next chapter in your life and wish you well. I guess the other big news on the leadership front is my appointment as CEO, which Adam covered at the start of the call. And I'll make my comments on this topic brief as well. First, I want to say I'm incredibly grateful to be cancer free today.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

And I want to thank the doctors, nurses and other medical staff at MD Anderson in Houston, which is, if any of you have friends or family, it's a world class institution that literally saved my life. Thank my family, my friends and all the people at Celebrite that were supportive, during the six months of chemo, which is not anything I'd wish on my worst enemy, for all their steady and continued support. And I want to steal this moment just to make a public service broadcast. I had no idea fourteen months ago that I was sick. I was talked into doing a proactive full body scan by a friend, only discover a week later I had stage four cancer and tumors all over my body.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

That scan literally saved my life. And I would just tell you, if you're over 30 and if you're on this phone, you've got the financial means, go get one of these scans. And if anybody has any questions about it, email me directly. I feel like it's one of my missions and purposes in life is to share that. And I promise I'll promptly reply and share my experience with you because it was literally lifesaving.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

So I've been asked repeatedly by friends, family and business colleagues, why do you continue to work at your age and as a cancer survivor? Or minimally, why didn't you take a medical leave? And the answer is simple. And this is an honest, genuine response. If it were any company other than Celebrite, that's precisely what I would have done.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

But I've never had the privilege, and I would argue in this case, the obligation to lead a company that truly makes the world a safer place every day. I love this company. I love our people. And I love our customers who are the brave men and women that risk their lives every day to make our lives a little better and a little safer. I'm grateful for my cure.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

And I can tell all of you, I couldn't be more energized to ignite a new and exciting chapter for Celebrite. There's a lot of work to do to combat bad actors around the world, but I and the 1,200 strong Celebriters embrace and welcome that challenge every day. Let me close with a view to the overall market. The macro tailwinds that have driven the expansion of our business remain strong and are arguably improving. Unfortunately, the usage and sophistication of technology in the pursuit of crime continues to climb and technology like ours is the best and most efficient path to preserving public safety.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

As we move into the second half of the year, we anticipate healthy growth across the majority of our regions and segments with sequential acceleration in our ARR over the next two quarters. The one sector in our business that carries second half uncertainty despite a robust pipeline and strong demand signals is the timing of orders from our U. S. Federal segment. To be clear, we believe that Celebrite is incredibly well positioned with highly differentiated solutions that enable our federal clients to better execute on the new administration's priorities around things like border protection, drug enforcement, human trafficking, child exploitation, sovereign security and overall operational efficiency.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

We view the recent legislation in The U. S. As a catalyst that will soon convert the current spending headwind into a tailwind. Based on the ongoing dialogue with our customers, we expect these needs will lead to a resurgence of growth in 2026. Early signs of improved spending in this sector are already starting to surface.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

One of our longstanding U. S. Federal law enforcement customers recently increased its 7 figure annual spend on Celebrite's portfolio that includes both our digital forensic software and Pathfinder. The agency is also moving forward with its plans for its insights conversion, which will improve their process for collecting and reviewing digital evidence. And the opportunity in this agency, lastly, is further enhanced with our pending FedRAMP ATO authorization and the associated ability to leverage and deploy our Guardian solution.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

It's also important to note that renewals are proceeding smoothly with retention levels for this sector well above the corporate average for retention and renewals in the mid 90% range. Although the mid to long term demand signals remain vibrant, we believe it's prudent to modestly adjust our full year ARR and revenue expectations until we see purchasing activity in The U. S. Federal segment return to more conventional cadence. Last quarter, I referenced the fact that this sector was 17% of last year's ARR and it had a 25% CAGR over the past three years.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

The reduction in our twenty twenty five U. S. Federal ARR growth translates to approximately four points of total ARR growth for the company this year and also accounts for the majority of the revised full year guidance. As we have shared repeatedly, our income statement and our emerging scale carries leverage. And if and when we experience a short term dip in our historical growth rates, we possess and we will execute the requisite spend discipline to continue to deliver expanding EBITDA and free cash flow, all without compromising our ability to capitalize on the large long term opportunity for growth and market share.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

We have leveraged AI across all functions to protect growth and innovation and consequently have scaled back planned hiring in 2025. Our disciplined approach to spending has translated to the elevation of the low end of our existing EBITDA guidance and will ensure another exceptional year for free cash flow. In summary, the need for Celebrate's purpose built solutions for public safety has never been higher. Every day, we literally witnessed the impact of our technology, whether it's helping save children from being trafficked into a life of horrible abuse, dismantling fentanyl distribution channels or putting murderers behind bars. We'll continue to grow at healthy rates in spite of short term headwinds in federal.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

We are leveraging our scale to improve our margins, net income and free cash flow. We're optimistic that when the federal market turns, it will turn with a vengeance. What is equally exciting about Celebrite are our plans to catapult our value through a powerful combination of AI driven internal innovation, strategic partnerships and targeted acquisitions. We have big plans for this company and I look forward to that journey as its leader. With that said, I'll now turn it over to Dave.

David Barter
David Barter
CFO at Cellebrite DI

Thank you, Tom. Before I review the second quarter results, I'd like to briefly describe why I am so excited to serve as Celebrite's CFO. I think you'll find that many of the same characteristics that appeal to me as a CFO likely resonate with those of you in the investment community. First, like other leading vertical software companies, Celebrite has compelling secular tailwinds with high barriers to entry on account of our purpose built software and the relationship we maintain with our customers. Second, we are fortunate to have an experienced team with deep domain expertise that is motivated by the mission and commitment to public safety.

David Barter
David Barter
CFO at Cellebrite DI

The Celebrite team operates with incredible focus. We deeply care about partnering with our customers who make a real difference in protecting life and our communities. And finally, Celebrite is regarded as the clear product and technology leader. This allows us to build a business that not only serves our customers well, but it also produces durable top line growth, attractive profit margins and very meaningful levels of free cash flow. Let's move on to the review of our second quarter results.

David Barter
David Barter
CFO at Cellebrite DI

ARR grew 21% to $419,000,000 Our growth was primarily driven by increased spending within our customer base. The Americas represented 54% of total ARR, while EMEA represented 34% and Asia Pacific was at 12%. In terms of growth rates by geography, The Americas grew 24% led by excellent expansion within U. S. State and local government and Latin America.

David Barter
David Barter
CFO at Cellebrite DI

ARR grew 21% in the Asia Pacific region followed by 17% growth in EMEA, which improved sequentially from Q1 levels. In terms of product family performance, Insights has continued to see healthy ARR growth as customers continue to upgrade from our legacy software to the Insights solution. More than 40% of our installed base was using Insights at the end of the second quarter. We also continued to see strong growth for our unlock offering, which is now attached to more than 40% of the Insights and legacy customer base. On a combined basis, Guardian and Pathfinder continue to grow faster than our overall ARR.

David Barter
David Barter
CFO at Cellebrite DI

These two products now represent approximately 10% of our total ARR. One other important milestone worth repeating, our cloud enabled and SaaS solutions reached 20% of total ARR this quarter, which reflects over 50% growth in these offerings. Turning to revenue, we generated second quarter revenue of $113,300,000 which increased 18% from the prior year due primarily to subscription revenue growth of 21%. Approximately 91% of total revenue was associated with subscription based software solutions. This growth translated into improving levels of profitability.

David Barter
David Barter
CFO at Cellebrite DI

Our gross profit increased 20% to $96,400,000 which represents a gross margin of 85. Second quarter adjusted EBITDA of $27,900,000 increased 29% over the prior year and the margin increased 200 basis points to 24.6%. We're pleased with this operating leverage. As a company, we are focused on maintaining a powerful combination of healthy revenue growth and thoughtful capital allocation to key investments that we believe will lead to increased product adoption and long term durable and profitable growth. We ended the quarter with twelve sixteen employees.

David Barter
David Barter
CFO at Cellebrite DI

We reported second quarter operating income of $26,200,000 with non GAAP net income of $30,800,000 or $0.12 on a fully diluted basis. Overall, our average weighted diluted shares outstanding increased slightly from first quarter levels. It is important to note that our weighted average share count has started to stabilize. We expect relatively minimal dilution going forward. Let's turn to the balance sheet.

David Barter
David Barter
CFO at Cellebrite DI

We ended the second quarter with $558,000,000 in cash, cash equivalents and investments, an increase of $48,000,000 from the 2025 and an increase of 191,900,000 compared to the prior year. Free cash flow for the second quarter was $29,000,000 and the free cash flow margin was 25.6%. For the trailing twelve months, free cash flow was $150,000,000 or 34% on a margin basis compared to $91,000,000 or a 25% margin in the previous period. In terms of upcoming uses of capital, our acquisition of Keryllium will lead to a net cash outflow of $150,000,000 when transaction closes. The company reported ARR of approximately $15,000,000 at the June.

David Barter
David Barter
CFO at Cellebrite DI

We plan to share additional details around Keryllium and its financial performance when we report Q3 results in November. Prior to sharing our outlook, I'd like to share some perspective as to how we developed it. As a reminder, we have historically generated the majority of our ARR revenue and adjusted EBITDA in the second half of the year. We anticipate this trend will hold true in 2025. Our guidance is informed by several inputs.

David Barter
David Barter
CFO at Cellebrite DI

First, there is a sizable base of remaining performance obligations or RPO. Second, we assess expiring agreements including renewal timing and the related expansion opportunity across our customer base. Our model contemplates our gross dollar retention, which has been in the lower 90 range. Third, we consider the contribution of new business from customers expressing a need to expand in the middle of their agreement terms. And finally, we look at new logos, which tends to be a smaller contributor to ARR and revenue given our land motion.

David Barter
David Barter
CFO at Cellebrite DI

We anticipate that our third quarter ARR will grow sequentially in the mid single digits followed by a similar increase in the fourth quarter. This is stronger than the sequential growth we saw in the first half. We are planning for temporary delays with U. S. Federal agencies.

David Barter
David Barter
CFO at Cellebrite DI

While customer interest and engagement in this sector is high, we are planning it will take time before the recent U. S. Legislation will help drive higher spending on Celebrite by U. S. Federal agencies.

David Barter
David Barter
CFO at Cellebrite DI

We believe it is prudent to adjust our outlook until we have clarity on the timing of orders. We expect third quarter twenty twenty five ARR in the range of $435,000,000 to $445,000,000 or growth between 1720%. We now expect full year ARR of $460,000,000 to $475,000,000 or growth of 16% to 20%. This updated outlook assumes minimal growth from U. S.

David Barter
David Barter
CFO at Cellebrite DI

Federal customers. The change to our growth assumptions around U. S. Federal customers impacts our total ARR growth by approximately four percentage points. Factoring in the update to our anticipated ARR growth for 2025, we now expect third quarter revenue to be in the range of 121,000,000 to $126,000,000 or growth of 13% to 18%.

David Barter
David Barter
CFO at Cellebrite DI

We expect full year revenue in the range of $465,000,000 to $475,000,000 or growth of 16% to 18%. We expect our Q3 gross margin to be within our full year 2025 gross margin target range of 84% to 85%. We remain focused on thoughtful capital allocation to fund the investments we believe are critical to addressing customer needs and fueling durable growth over the long term. We expect Q3 adjusted EBITDA in the range of 31% to 34% excuse me, we expect Q3 adjusted EBITDA in the range of $31,000,000 to $34,000,000 or approximately 26% to 27% on a margin basis. For the full year, we now expect adjusted EBITDA in the range of 118,000,000 to $123,000,000 or 25% to 26% on a margin basis.

David Barter
David Barter
CFO at Cellebrite DI

And finally, I'd like to reiterate our view that 2025 will be an excellent year for free cash flow. Given the strong cash flow from operations thus far into 2025 and relatively minimal capital intensity, we expect the company's free cash flow margin will be approximately 30%. In summary, Celebrite remains well positioned to deliver another year of healthy growth, strong profitability and excellent free cash flow with a minimal amount of dilution to shareholders. This concludes our prepared remarks. Operator, we're now ready for Q and A.

Operator

The floor is now open for questions. At this time, if you have a question or comment, please press 1 on your telephone keypad. Our first question is coming from Shaul Eyal with TD Cowen. Your line is open. Please go ahead.

Shaul Eyal
Managing Director - Equity Research at TD Cowen

Thank you. Good morning, everybody. Congrats to everyone on their new roles and also on solid performance, which appears to be more timing driven. Tom, thanks for the honest and candid comments regarding your personal health. Glad the process is behind you.

Shaul Eyal
Managing Director - Equity Research at TD Cowen

Donna, wishing you nothing but the best. It has been a pleasure working with you over the past few years. Two part question on my end, if I may. Tom, what's your confidence levels as we think about this ongoing recovery in federal spending? And maybe the second part for David, as we think about your retention rates this quarter, can you outline to us any key drivers, anything which has been tied to U.

Shaul Eyal
Managing Director - Equity Research at TD Cowen

S. Federal spending and agencies in that regards? Thank you.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

Yes, I'll take the macro. And by the way, thank you for your kind words. It's much appreciated. Let me take the macro and then I'll let a mix of maybe Dave and Marcus comment, on the renewals, because there's actually a good story behind that story. But at a macro level, I would tell you the confidence level is high.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

When you script these things, as you guys know, everybody's very careful about what you say. So for me to tell people that when this turns, it's going to turn with a vengeance, I don't I wouldn't use those words lightly, which I think is a good harbinger indicator of how we feel about the business in federal. And we're seeing strong renewals. I talked about renewal rates in the mid-90s. And we're going to talk we'll comment on one specific transaction that actually has a positive kind of back end and ending to this.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

But the macros that drive who we are, unfortunately for all of us, they're not only not going away, they're getting worse. I mean, crime is not going away and the sophistication and usage of digital, is becoming more pervasive. Whether you're an intelligence agency, whether you're a defense agency or local law enforcement, you don't have enough labor and budget dollars to hire labor to try to navigate and prosecute the amount of data needed to drive safety, both at a sovereign security defense level or a state and local. So the demand drivers are not going to go away, unfortunately, I don't know, for at least, I think a decade. And so that's there.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

Our product and our portfolio, we still are highly convicted is market leading in the industry. And when we talk to the customers in federal, the talk track isn't geez, I don't know, they're frustrated because they need and want our product and they're waiting for the BBB to get passed. And now they're waiting for that to trickle down and that's just going to take a little bit of time and that doesn't really kick in until October 1 anyway. And so but our view is once that new fiscal cycle and the allocation of I'm told roughly $2,000,000,000,000 of budget that's been allocated to the D and I segment, which is where we're very focused. Those things combined with the pending ATO ability to deploy our cloud based assets in the federal government, lead us to be super bullish about 2026.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

And we just this company has a reputation and I think all of us here of transparency and integrity in reporting and our guidance. And rather than hope or predict when that trickle down is going to hit, our strategy has been to call it as we see it right now. And when the wave hits the beach, we're going to be delighted to share that news and we think that tsunami is coming. But let me let Dave and Marcus comment on the renewal thing because there's a really positive story in that as well.

David Barter
David Barter
CFO at Cellebrite DI

Thank you for your question. It's a great one. I think maybe as context, our federal business has traditionally operated when you think about our gross dollar somewhere between mid to really upper 90s, and this quarter there was certainly one particular transaction where we have multiple customers this customer has multiple contracts and one of their contracts as they were preparing for the new legislation ultimately did start to slip out of the quarter. So I'm going turn it over to Marcus to give you a little bit more color, but that was one element that ended up weighing on the statistic and figure that you have in mind.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

Sure. Thank you, David. I think I can bundle this up. In Q1, we actually talked about in the Q1 call, there was a retention of a large contract, which was looking delayed. This was a program based, which through the Doge confusion, the program did not get renewed.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

However, the customer need is only increasing. It's a shame that we can't talk about the customer specifics on the call because you would then understand how important this is for civilian safety. And we are now bidding an agreement, which we expect to be roughly 2x in size and the customer is still an active customer. So what I would say is we have a new bid. We are confident with our technical position and we are waiting for the flow after tenone to be able to get that back on the docket.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

Yes. So to summarize that, pain point for a delay, but we have high expectations and optimism that they will recommit. And the better news is when they do, and we think that'll be in the next one to two quarters, that renewal actually would be 2x the old renewal. So that's if every federal customer renewed at 2x, we'd be in a really happy place. But we think that's a good indication of the stability in demand and just points back to the timing issue.

Shaul Eyal
Managing Director - Equity Research at TD Cowen

Understood. Thank you so much. Yes. Thank you.

Operator

We'll go next to Mike Cikos with Needham. Your line is open. Please go ahead.

Mike Cikos
Senior Analyst at Needham & Company

Hey, guys. Thanks for taking the question here. And I'll echo Shaul's comments. Great to hear on the personal health front, Tom. Donna, I'm sorry to see you go, it's been an absolute pleasure working with you these last few years.

Mike Cikos
Senior Analyst at Needham & Company

And Dave, I'm looking forward to working with you again given our shared time over at New Relic. I think the first question I just wanted to get at, I know that you guys all walked through different intros and your views and whatnot, but David really in going through this transition process with Donna recently, Curious to get a sense, what are some of the initial findings that you've uncovered? How do you view your role here at Celebrite, and is there any change that we should think about as far as different levers you plan on pulling? Is the company willing to reiterate the targets that it disclosed previously at the Investor Day? Anything there from a longer term or vision standpoint would be beneficial.

David Barter
David Barter
CFO at Cellebrite DI

Okay, well Mike and I too am looking forward to working with you, it was a real pleasure working with you at New Relic and this will be a ton of fun. I guess maybe at a fundamental level, I should actually be remiss if I didn't start with thanking Donna, She's been just fantastic to partner with over the last month and her generosity and her commitment has been fantastic. I think from a values perspective, I think you'll certainly find us very similar, Certainly, quite frankly, as we've built the financial model for the second half, I think we have the same orientation almost in terms of having a bottoms up view in terms of how we build our outlooks for ARR for revenue. Arguably on the cost structure. I think we share a similar philosophy almost around zero based budgeting of how do you build yourself up from bottom to top to make sure that you're funding and putting headcount in all of our capital relative to things that we think are really pro growth, and in some cases that is areas around product, in other cases it's around how you put AI into product or AI how you put it into our processes.

David Barter
David Barter
CFO at Cellebrite DI

And so it sounds like, I don't want to belabor the point, but think Donna and I kind of think and work very similar ways. In terms of kind of thinking about our approach on Analyst Day, I'll kind of come back to you. I think similar to Donna, I usually build the operating plan for which we'll start to offer perspective as we get into the latter part of autumn and into November, and then we will certainly refresh the long range plan in the spring. So happy to share more on that, but again I think you'll find the way I work, again similar to New Relic is very similar to the way Donna has been working. Does that help Mike?

Mike Cikos
Senior Analyst at Needham & Company

It does, thank you very much Dave, I really appreciate it. And a follow-up here for Marcus or Tom, just given the commentary, great to hear on that 2X sizing, even though we're facing that near term pain you had alluded to. Is there anything else you can point us to, Tom? I was really the comment from your prepared remarks that we're seeing early signs of improved spending already starting to surface. Anything else that you would point us to beyond this one agency here that we can kind of hang our hats on as we think about what the spending environment looks like or how it's evolving?

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

Yeah, I'll let Marcus comment, but there are two data points. One is just the funding, that is being released in spite of the drive for efficiency ends up landing in our sweet spot, which is why we're actually it's a tough pill right now because we're pretty bullish about the mid to long term. We're right in the strike zone of what the administration wants to go fix and where they've allocated dollars. And the other data point that we didn't get into in the script or call is our coverage and our pipeline in the federal segment is very strong. And so that combined with the recent signing of a meaningful deal that came in early in the quarter, that was the size of this other big deal that we think will still take a quarter or two, but we think is going to be minimally 2x.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

Those are a bunch of data points. And Marcus, you could add more color or confidence.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

Yes. I think there's three points I want to orient to. So first of all, the federal government that we referred to is the U. S. Federal government.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

When we look outside of the U. S. Federal, central government spending is increasing at a clip in both the defense and intelligence. And what that points to is that the use case is correct, our return on investment is correct, but we are caught in a spending issue as many, many operators are currently in The U. S.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

Federal. The second thing is the indication as we look at our renewals in this quarter from a bookings perspective are increasing in terms of value. So we see a value increase in renewals, which again points to an extension of what we do. And then the two other points to think about is the interest in Carilion is exceptionally high. As you can imagine, we talked about our initial deal in Europe for an intelligence bureau.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

And we're actually seeing that interest grow into the federal government into the decision makers we already know and expansion of use case. And then let's not forget that we're now preparing for being first in the market with a Fed level high secure cloud forensic solution, which will give another big tailwind to our business when we are ready to execute on that program.

Operator

We'll take our next question from Eric Martinuzzi with Lake Street. Your line is open. Please go ahead.

Eric Martinuzzi
Senior Research Analyst at Lake Street Capital

Yeah, I wanted to follow-up on the issue from Q1. There was US Federal, and then it seemed like there was also some European pipeline issues. Based on the results of Q2, it looks like that is we're not facing that anymore in Europe. Is that the case? Are we back on track as far as defense and intel pipeline Europe?

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

Yeah, great. I'll do the quick voiceover, and then I'll let Marcus fill in the blanks. But we're, we are our European leader has done a nice job of implementing, I think, a really thoughtful strategy. You could argue he was a first mover on the focus on D and I, which is starting to pay dividends and we're seeing ramps in both growth rates and pipeline and we're pretty bullish about Europe. So there's still work to go, but your observation I think is spot on, Marcus?

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

Yes. I mean, think it's just great execution. We talked about a pivot in our strategy. We felt that we hadn't we didn't have enough share in the D and I market outside of The U. S.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

Ed Dohlman, leader there has done a great job in re pivoting and covering and we've had significant orders in D and I and we continue to see an acceleration there. And we're playing into a nice area because of the NATO spend increases. So we see continued strength in Keryllium has only shown that as well. And obviously, our first resale order of Keryllium into Europe is showing the way and we very confident about our growth rates in EMEA going forward.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

By the way, you step back geopolitically and the logic is pretty obvious with The U. S. Pressuring, the EU to step up on their defense spending. When you look at the conflict with Ukraine and Russia and the issues that, that presents from a border protection issue around the EU, those are all initiatives that benefit from the Celebrite portfolio. And the spend on Celebrite relative to the increased focus and spend by the EU countries to address both of those issues, is the perfect storm for us and the reason that we're focused on it and the reason we're starting to see the traction.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

Yes. There's also one thing to add, Tom, and thanks for pointing my direction there is that the migrant crisis in Europe is the worst it's been and there is significant additional funding being added And we are right in the midst of securing those funding opportunities for incremental business in new task force, which are being formed across Europe to deal with the migrant crisis.

Operator

We'll move next to Bhavan Shah with Deutsche Bank. Your line is open. Please go ahead.

Bhavin Shah
Bhavin Shah
Director - Software Equity Research at Deutsche Bank

Great. Thanks for taking my questions. I echo the statements both Shao and Mike mentioned at the beginning of the statement. I guess, just a clarifying question on the guidance.

Bhavin Shah
Bhavin Shah
Director - Software Equity Research at Deutsche Bank

Tom, you mentioned the four point kind of impact they are just from kind of the changes in assumptions you made around the timing of US Federal. Just what else is going to the remainder of the reduction? Where are you kind of being a little bit more conservative? Are you seeing anything else in the macro that's gotten you more cautious on the ex federal side at the remainder of the year?

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

I'll let Dave comment on that. Other thing that we didn't get into the details is we had a pretty modest quarter in the private sector. But there's another when you start looking for logic, for increased optimism around growth in 2026, the Keryllium asset is a big play in D and I as Marcus just mentioned. But sort of the hidden secret here is we think Keryllium has massive potential in our private sector business. So, it's still a small part of our P and L. I think it's what 7% or 8%?

David Barter
David Barter
CFO at Cellebrite DI

Correct.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

So it's not a big contributor. But when you look at the balance of the business, whether it's product, geography, cohorts, we're pretty bullish about growth. You look at for example, if you look at our growth in the SLG business this year, I don't know if we disclosed that number, but it's been strong. And no correlation with budgets and doze or anything else. The uptake there has been exceptional.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

But Dave, I don't know if you would add anything to that.

David Barter
David Barter
CFO at Cellebrite DI

I guess the only compliment is I think we have a very detailed process of going through and assessing our deals and looking at gross AR, looking at deal timing, and I think we've just been very thoughtful in the build and the primary driver here is Fed and then we've really, I think, tightened up the forecast across all of our sales patches. So, I think we feel good about our plan for the next six months.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

I know it's easy to oversimplify, but the truth in this case is if the federal business showed up this year like they have the last three years, we'd be positioned to meet or exceed, on the top line and probably the same on the I mean, we're delivering on the bottom line in spite of the federal headwinds. So it really is and again, it's not a we're not losing to any competition. It's not that demand is going away. It's a timing issue that we just need to navigate and get through.

Operator

Our next question comes from Brian Essex with JPMorgan. Your line is open, please go ahead.

Brian Essex
Brian Essex
Executive Director at JP Morgan

Hi, good morning. Thank you for taking the question. First of all, Tom, congratulations on the health battle. It's fantastic news. And then, Dana and David, congratulations to you as well.

Brian Essex
Brian Essex
Executive Director at JP Morgan

David, looking forward to working with you. Maybe for Tom, to follow on some of the federal questions, could you maybe educate me a little bit on the sales cycle and where you're seeing the bottleneck? Is this merely just a wallet issue? I think we've heard from some peers that sell into that vertical that there's been some headcount turnover and maybe finding the right person to sign off on a deal was the bottleneck. But how do you kind of go what's the sales cycle like? Do you find a sponsor that commits to the platform and then that sponsor gets approval and then someone just needs to write a check?

Brian Essex
Brian Essex
Executive Director at JP Morgan

Like how do you is this a procurement process issue or is this more of a sponsorship penetration issue? Maybe just give us a little bit of color around that.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

Sure. Tom's pointed to me, so as a CRO, I'm going to take that one. CRO has always loved to overcomplicate the sales process. I'm going to break it down to the four simple things. The federal government effectively what you do remember, we're on the mission side of the business.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

We're not in the general IT side. So we serve the mission. And so most of our work is done through programs, grants and baked into the core budget. So what happens is first of all you understand the needs, you then present the solution and then you win the solution technically. And that is effectively you're the chosen technology and the return on investment which in our case is saving lives, which is a pretty high return on investment is approved.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

Then you're in the final part, which is what program are they going to use, what budget they're to use. All of the business is stuck in that fourth element. It is literally, I think 50% of the decision makers in central government have been changed. CIOs have been changed, mission people have been changed. And we are working through flow of funds and getting the new resolution signed.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

And it is literally that is right at the tail end of the deal. It's not a qualification or an execution issue. It is flow of funds, which start coming after tenone as Tom said. So I can't point to any major changes of regime or culture or different sentiment. Literally the budgets were frozen, they've been reissued and they've got to work through the procurement systems now and the right programs have to be applied and we will start seeing things flow.

Operator

Our next question comes from Jeff Van Rhee with Craig Hallum. Your line is open. Please go ahead.

Jeff Van Rhee
Partner, Equity Research Analyst at Craig-Hallum Capital Group LLC

Great. Thanks for taking the questions. And Tom, glad to hear the conviction around the health to take the permanent role. David, welcome. And Donna, it's been a phenomenal run.

Jeff Van Rhee
Partner, Equity Research Analyst at Craig-Hallum Capital Group LLC

You've been just a pleasure to work with. So wish you the best. A couple for me, if I could. Tom, in terms of the AI progression and how your vision for its impact on the Celebrite business has evolved, talk to me about your thinking both internally and externally, the optimal way to employ AI and the benefits you think you can see from it.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

Yes, it's a great question. And I'm going to answer it, Jeff, at a higher level because, we actually have really we have aggressive, ambitious plans for how we're going to leverage Gen AI to differentiate this company and think we believe it'll be an enabler for the next chapter of growth and TAM for us. So that's how important we view AI in general. I'll just say that upfront. And your question is spot on because it is a hybrid of internal efficiency.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

So, we are using AI, across the company already, to drive efficiency. And I alluded to it, in how we've managed to meet or beat bottom line while we've had some softness from U. S. Federal. Some of the steps we've taken there have enabled us to maintain our delivery commitments, with the same or similar amounts of people, which is different from what we planned at the beginning of the year.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

So and by the way, this isn't just the obvious thing people point to is, hey, are you using AI for code development in R and D? Yes. And that's still early innings. But it's not just R and D. If I asked Marcus, he can talk about some really amazing things that our CIO is driving right now with AgenTeq bots and assistance to help drive productivity and efficiency in our sales forecasting and our sales operations area.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

If I ask Dave and Donna, they're doing work and they're finding areas to apply AI in the financial operations space. So that's across the board and it's just getting started. Externally, if this was a cone of silence, I'd give you more details, but we know that these calls include our competitors. And I would just tell you that we are only just getting started in the art of the possible of applying AI to the challenge of public safety when you think about the breadth of diversity of evidential artifacts. You think about the data from a cell phone, which is the most valuable and the hardest to get, but then you add on top of that data like CCTV, fixed cameras, drones, ballistics, license plate, tower dumps.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

I mean, the list goes on and on. It becomes daunting and the ability to navigate and interrogate the breadth of those data sources, with a machine and an LLM that's been trained, to deliver value and insights to investigators, detectives, corporate compliance people, the field is saying, You ain't seen nothing yet. And so, that's probably more than I want to share right now, but it's going to play a big role both internally and externally.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

I think there's one thing we're not going to do. We're not going to just put an LLM in front of our product and say we're an AI company. I mean that is just a poor use of AI. That is and I think people need to see through that. Is about using AI to deliver a better outcome, which has multiple threats as Tom alluded to.

Andrew Kramer
Andrew Kramer
VP - IR at Cellebrite DI

So, we're getting close to time. I know that there's a couple of people who've signaled in, so we want to be sensitive to try to get their questions in. We'll extend the call for another few minutes. And operator, if you want to open the line for the next question.

Operator

We'll go next to Tomer Zilberman with Bank of America. Your line is open. Please go ahead.

Tomer Zilberman
Tomer Zilberman
Associate - Equity Research at Bank of America

Hey, guys. I'll echo similar sentiments from before. Tom, first of all, congrats on recovery. Donna, thank you for your partnership for the last few years. And David, looking forward to working with you.

Tomer Zilberman
Tomer Zilberman
Associate - Equity Research at Bank of America

We're now in the third quarter of this weaker Fed discussion. I just want to ask, are you seeing any more degradation in the Fed environment as it pertains to what you mentioned earlier about regime changes, pausing on budgets? Are you seeing weakness or further weakness there? Or is it just this constrained visibility that's giving you this incremental caution?

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

No. I mean, there's basically zero indication of weakness. As I said, our two drivers are the use of mobile technology and bad people doing bad things. Both tend to increase. So we don't see any detriment.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

And in fact, we're more confident in our competitive position than we have been as we extend our technology advantage. So no, it is purely on the financial side and the budget releasing.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

And by the way, I would just reiterate, the renewal rates in this segment remain extremely solid and strong. So that'd be the first place if that were happening, that'd be the first place you'd see it as people would start to scale back or downsize, downscale their commitments. We've seen none of that.

Operator

We'll go next to Louie DiPalma with William Blair. Your line is open. Please go ahead.

Louie Dipalma
Research Analyst - Industrials at William Blair

Tom, Adam, Donna, David, Marcus, and Andy, good morning. Tom, health and life is paramount, so congrats on the favorable diagnosis and your appointment as CEO. And, Donna, it was thoroughly enjoyable to work with you, and congrats on the tremendous success that you've experienced at Celebrite over the years. And and, David, congrats on on joining Celebrite. Lots of congratulations.

Louie Dipalma
Research Analyst - Industrials at William Blair

But for for my for my for my question, I just wanted some more commentary on investors are focused on on the long term. And, Tom, you discussed how you expect a resurgence in 2026. And I was just wondering if you could provide more elaboration on that. Thanks.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

Well, I mean, if you look at what those growth drivers are, there's list. We talked about Guardian doubling year over year for fourth straight quarter. That's pretty good. It would be great to get the entire portfolio doubling. But the penetration of Guardian is still a fraction of the opportunity.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

And so we've got a lot of runway and the pipeline there, which we I don't think we disclosed, but the pipeline in Guardian has continues to explode in parallel with the year on year growth. So all indications are and by the way, from a capability perspective, and value delivered and also more comparative data between Guardian and other options for repositories, all those things are extremely positive and give us, a lot of confidence in Guardian continuing to be a growth contributor. We're targeting 50% I think the target we gave was 50% for Insights. So that tells you when we look to 26%, you still have half of our installed base. And by the way, the people that are converting, the feedback has been extremely positive.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

So the value prop we're delivering with Insights is resonating. And so that is a built in growth driver for 2026. In the federal space, we beat that to death. The only good news about having a tough year, is your year to years look a lot better than next year. And so and as I said earlier, we think it'll turn and when it does, it'll turn hard and strong, with all the capabilities, the focus on D and I, global allocation of dollars to D and I, our ATO certification, which we expect to get in early twenty twenty six.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

That gives us a bunch of tailwinds in the federal business. And the analytic piece that I just touched on, Keryllium, which we think we're going to turbocharge that business based on just customer conversations we've had in the last four to six weeks, people are off the chain interest in that asset. So we're excited about what that can do for growth. So there's a lot of work to do. We got to execute, but there's a lot of cause for optimism as we look to January in 2026.

Marcus Jewell
Marcus Jewell
Global Chief Revenue Officer at Cellebrite DI

Yes. I'd like to add, we can we are now in the lead of the ability to analyze and virtualize any ARM based system, which so it's worth counting up how many ARM based systems and sensors are across the globe gives us a huge opportunity to add to our growth story.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

One last thing I will add is we've been working hard as a team since I stepped into the interim role in January on strategy. And the strategy is all about how do we better serve our mission globally and what can we do that's a logical significant expansion in our TAM. And we're pretty fired up about the vision we have. Obviously not here to disclose any of that, but in addition to everything you know and everything we just shared, there's a bunch of new internally driven innovation from R and D. We've got some interesting partnership conversations in flight in the market and we continue to scope the market for strategic and thoughtful M and A.

Thomas Hogan
Thomas Hogan
CEO & Director at Cellebrite DI

And those are all additive to the organic things I outlined.

Operator

This concludes the Q and A portion of today's call. I would now like to turn the floor over to Andrew Kramer for additional or closing remarks.

Andrew Kramer
Andrew Kramer
VP - IR at Cellebrite DI

Thank you very much, Angela. Thanks again to everybody for joining us today. Appreciate your patience, with the long, call that we ran today. We look forward to engaging with you, over the coming days, weeks and throughout the quarter. So, if you do have questions, feel free to reach out directly to me. Thank you.

Operator

Thank you. This concludes today's Celebrite second quarter twenty twenty five financial results conference call. Please disconnect your line at this time, and have a wonderful day.

Executives
    • Andrew Kramer
      Andrew Kramer
      VP - IR
    • Adam Clammer
      Adam Clammer
      Chairman
    • Thomas Hogan
      Thomas Hogan
      CEO & Director
    • Dana Gerner
      Dana Gerner
      Advisor, CFO
    • David Barter
      David Barter
      CFO
    • Marcus Jewell
      Marcus Jewell
      Global Chief Revenue Officer
Analysts
Powered by Quartr